Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3155 - A clinically applicable model to predict risk of relapse in patients treated for locally advanced breast cancer. Potential utilization in future clinical trials.


11 Sep 2017


Poster display session


Breast Cancer


Olexiy Aseyev


Annals of Oncology (2017) 28 (suppl_5): v68-v73. 10.1093/annonc/mdx364


O. Aseyev, L. Simmonds, M. Gertler, S. Verma

Author affiliations

  • Medical Oncology, The Ottawa Hospital Regional Cancer Centre, K1H 8L6 - Ottawa/CA


Abstract 3155


Despite advances in cancer treatment, over 25% of patients (pts) with locally advanced breast cancer (LABC) relapse during first 5 years after treatment. The primary objective was to construct a prediction tool for risk of relapse (RR) in pts with LABC after neoadjuvant therapy (NAT).


This was single center, retrospective study of 546 pts with LABC who received NAT at the Ottawa Hospital Cancer Center between 2005 and 2015. Median follow-up was 49 months. The following data collected: demographics, tumor size, nodal and receptor status, grade, HER-2, stage, treatment and clinical outcomes. Primary endpoints were local and/or distant recurrence rate and time to relapse during the first 5 years. A prediction tool was devised based on the Cox regression model.


Over 60 variables were included in primary analysis. Cox regression proportional hazards model analysis resulted in only 5 factors with significant influence on risk of relapse during first 5 years of follow up. Risk factors and their risk prediction value are: 1) residual disease (yes- 4; no-0), (HR = 4.25; p-value


Patients with LABC represent a heterogeneous group with diverse risk of disease recurrence that can be predicted. Patients with high risk may require additional treatment and/or more active follow-up strategies and this simple model may be used to design unique studies in LABC based on RP score. We intend to further validate this model on a larger multi center/provincial population.

Clinical trial identification

Legal entity responsible for the study

Olexiy Aseyev




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.